Zydus Lifesciences gets warning letter from USFDA for Jarod facility

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2024-08-31 06:00 GMT | Update On 2024-08-31 06:00 GMT

Ahmedabad: Zydus Lifesciences has informed in a BSE filing that the Company has received a Warning Letter from the US Food and Drug Administration (USFDA) relating to the Injectables manufacturing facility at Jarod near Vadodara.

The Warning Letter summarizes violations with respect to Current Good Manufacturing Practice (cGMP) regulations. It does not contain any data integrity related violations.

Earlier in July, the Company had received OAI status from the USFDA. The inspection which was conducted from April 15 to April 23, 2024.

"The contents of the Warning Letter shall be made public by the USFDA in due course," the Company stated.

"The Company will take all necessary steps to work with USFDA towards earliest remediation of the above facility," it added.

Zydus Lifesciences Ltd. is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. Zydus has been actively discovering and developing New Chemical Entities (NCEs) novel biologicals, several biosimilars and vaccines as a part of its innovation pipeline. Over the last decade, Zydus has introduced several products in the market for treating unmet healthcare needs with vaccines, therapeutics, biologicals and biosimilars.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Zydus Lifesciences gets warning letter from USFDA for Jarod facility

Similar News

COVID-19 Vaccine and Heart Attack: Biocon Chief, Karnataka CM get into war of words

Govt Panel Makes This Approval Mandatory For New Drug Licenses

CDSCO Panel Asks Glenmark To Justify BE Waiver for FDC Inhalation Suspension With Scientific Evidence

Sun Pharma Gets SEC Nod to Begin Phase III Trial of Cough Drug Gefapixant

USFDA grants priority review for Winrevair label update based on ZENITH Trial: Merck

AstraZeneca, Summit in discussions over USD 15 billion cancer drug licensing deal: Report

Bain Capital divests 2.4 percent stake in Emcure Pharma for Rs 563 crore

Shilpa Pharma Lifesciences Unit-1 successfully completes GMP inspection from Brazilian regulatory authority